USA - New York Stock Exchange - NYSE:NVO - US6701002056 - ADR
We assign a fundamental rating of 7 out of 10 to NVO. NVO was compared to 190 industry peers in the Pharmaceuticals industry. NVO scores excellent on profitability, but there are some minor concerns on its financial health. NVO has a correct valuation and a medium growth rate. NVO also has an excellent dividend rating. These ratings could make NVO a good candidate for dividend investing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| ROIC | 38.03% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.03% | ||
| PM (TTM) | 32.88% | ||
| GM | 82.05% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 1.66 | ||
| Altman-Z | 4.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.57 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.86 | ||
| Fwd PE | 16.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.97 | ||
| EV/EBITDA | 11.28 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.94% |
ChartMill assigns a fundamental rating of 7 / 10 to NVO.
ChartMill assigns a valuation rating of 6 / 10 to NOVO-NORDISK A/S-SPONS ADR (NVO). This can be considered as Fairly Valued.
NOVO-NORDISK A/S-SPONS ADR (NVO) has a profitability rating of 9 / 10.
The Price/Earnings (PE) ratio for NOVO-NORDISK A/S-SPONS ADR (NVO) is 15.86 and the Price/Book (PB) ratio is 9.68.
The financial health rating of NOVO-NORDISK A/S-SPONS ADR (NVO) is 6 / 10.